Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Erythrocyte-Targeted Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD235a / Glycophorin A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD235a ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD235a Products |
| Gene Delivery | CD235a Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD235a Products |
| Benchmark Ab | Anti-CD235a Benchmark Antibody Recombinant positive control. |
View CD235a Products |
| Validator | CD235a siRNA Set For knockdown verification. |
View CD235a Products |
| Related Target A | GYPB Homolog counter-screening and blood group complex analysis. |
View GYPB Products |
| Related Target B | CD47 Synergistic erythrocyte marker for immune evasion studies. |
View CD47 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycosylation-dependent Binding | HEK293 Expressed (Native Glycosylation) to preserve complex O-linked glycans. |
| Homolog Cross-Reactivity | High-purity GYPA and GYPB available for strict specificity screening. |
| Lack of Controls | Recombinant Benchmark Antibodies included for assay standardization. |
| False Positives | Sequence Verified siRNA included for specificity checks. |
Live CD235a / GYPA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The strategic utility of CD235a (Glycophorin A) is evolving beyond traditional blood typing and diagnostics. Modern therapeutics are leveraging CD235a for "erythrocyte hitchhiking"—a novel drug delivery mechanism where nanoparticles or engineered proteins bind to red blood cells to dramatically extend half-life and alter biodistribution. Furthermore, as a primary receptor for Plasmodium falciparum, CD235a remains a critical target in malaria research. The next wave of R&D is highly focused on precise, non-hemolytic erythrocyte targeting.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Targeted Delivery | Biotech Innovators | Extended Half-life / Oncology | Binding Affinity (Need native-glycosylated ECD-Fc) |
| Diagnostics | Major IVD Companies | Blood Typing / Hematology | Specificity Validation (Need GYPA vs GYPB panels) |
| Infectious Disease | Academic Consortia | Malaria (Plasmodium invasion) | Receptor-Ligand Assays (Need High-Purity Recombinant Proteins) |